Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

Contact
Request a demo
Request data updates
Add a company

Research

Companies
Investors
People

aVenture

Sitemap
Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage

Loading

Loading

Timothy Lu

AddedFeb 15, 2024

UpdatedMay 31, 2026

Timothy Lu

Timothy Lu

Co-Founder, Tango Therapeutics

Crunchbase LinkedIn The Org

Timothy Lu's Career

Tango Therapeutics

Tango Therapeutics

Boston, MA, US

Co-Founder

Senti Biosciences

Senti Biosciences

South San Francisco, CA, US

CEO· C-Suite · Management

Novophage

Boston, MA, US

Co-Founder

Corvium

Reston, VA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview

aVenture product preview

aVenture product preview

Timothy Lu's Career

Tango Therapeutics

Tango Therapeutics

Public$351M1102017Boston, MA, US

Co-Founder

Leadership at Tango Therapeutics

Barbara WeberBoard Member

José BaselgaCo-Founder

Cary PfefferBoard Member

William G. KaelinBoard Member

Alexis BorisyBoard Member

Antoni RibasBoard Member

Similar to Tango Therapeutics

Marengo TherapeuticsCambridge, MA, USCancer Treatmentest. 2015Marengo TherapeuticsCambridge, MA, US · est. 2015

Marengo Therapeutics: A clinical-stage biotech company dedicated to improving patient lives.

Series B · $80M36

GO TherapeuticsCambridge, MA, USCancer Therapiesest. 2014GO TherapeuticsCambridge, MA, US · est. 2014

GO Therapeutics, Inc.: A US-based biotech firm specializing in cancer-specific immunotherapies and drugs.

Series A · $5M11

TG TherapeuticsNew York City, NY, USCancer Treatments, Pharmaceuticalsest. 1993TG TherapeuticsNew York City, NY, US · est. 1993

TG Therapeutics: A biopharmaceutical firm innovating cancer treatments, focusing on non-Hodgkins lymphoma.

Public · $205M226

Window TherapeuticsBoston, MA, USCancer Treatmentest. 2021Window TherapeuticsBoston, MA, US · est. 2021

Window Therapeutics: A biotech firm innovating targeted cancer treatments for unmet patient needs.

Angel · $256k4

Senti Biosciences

Senti Biosciences

Public$215.9M1222016South San Francisco, CA, US

CEO· C-Suite · Management

Recent news

Latest News and Press ReleasesNews · 2024

Senti Biosciences plans holding company reorganizationNews · 2024

Senti Biosciences Holdings (Nasdaq:SNTI) - Stock AnalysisNews · 2024

Leadership at Senti Biosciences

Ed MathersBoard Member

Wilson WongCo-Founder

Laurent FischerBoard Member

Omid FarokhzadBoard Member

Philip LeeCo-Founder

Jim CollinsCo-Founder

Similar to Senti Biosciences

HubSpotCambridge, MA, USest. 2006HubSpotCambridge, MA, US · est. 2006

HubSpot, Inc.: A cloud-based CRM platform providing integrated tools for adaptable business operations.

Public · $100.5M7.4k

SalesforceSan Francisco, CA, USCRM, Softwareest. 1999SalesforceSan Francisco, CA, US · est. 1999

Salesforce provides cloud CRM and AI enterprise software for sales, service, and marketing teams.

Public · $65.4M70.8k

Think BioscienceBoulder, CO, USMedicinesest. 2019Think BioscienceBoulder, CO, US · est. 2019

Think Bioscience innovates synthetic biology, designing superior medicines using living systems.

Seed · $17.3M26

Senda BiosciencesCambridge, MA, USMedicinesest. 2017Senda BiosciencesCambridge, MA, US · est. 2017

Senda: Innovatively harnessing molecular interactions for advanced medicine development.

Series C · $309M80

Novophage

Series A$5.8M302009Boston, MA, US

Co-Founder

Leadership at Novophage

Mike KoerisCo-Founder

Tanguy ChauCo-Founder

Similar to Novophage

PhageProBoston, MA, USTherapeuticsest. 2016PhageProBoston, MA, US · est. 2016

PhagePro: Biotech firm developing bacteriophage-based therapeutics for vulnerable communities.

UniphageSan Francisco, CA, USBacteriophagesest. 2020UniphageSan Francisco, CA, US · est. 2020

Uniphage: A biotech firm using AI and bacteriophages to combat bacterial infections and citrus greening disease.

Angel · $256k1

Wild MicrobesCambridge, MA, USSustainable Productsest. 2022Wild MicrobesCambridge, MA, US · est. 2022

Wild Microbes: Innovating sustainable products through advanced microbial technology.

Pre-Seed · $3.3M4

NovoBiotic PharmaceuticalsCambridge, MA, USAntibiotics, Drugest. 2003NovoBiotic PharmaceuticalsCambridge, MA, US · est. 2003

NovoBiotic Pharmaceuticals: A private American biotech firm specializing in discovery and development.

Angel · $147.3k13

Corvium

Series A$35.9M2752009Reston, VA, US

Board Member· Board

Leadership at Corvium

Jeff SwartzBoard Member

Tim CurranBoard Member

Jeff BussgangBoard Member

Micah RosenbloomBoard Member

Michael KoerisBoard Member

Steve BlochBoard Member

Similar to Corvium

SafetyChain SoftwareNovato, CA, USFood Safety, Quality Assuranceest. 2011SafetyChain SoftwareNovato, CA, US · est. 2011

Cloud-based food safety and quality assurance solutions provider, SafetyChain Software, Inc.

Private Equity · $50M121

TraceGainsWestminster, CO, USFood Safety, Softwareest. 2008TraceGainsWestminster, CO, US · est. 2008

Tracegains Inc: A US-based software company enhancing food safety and quality with innovative technology.

Series A · $6M138

PheniumSan Francisco, CA, USFood Safetyest. 2016PheniumSan Francisco, CA, US · est. 2016

Phenium: Automated Food-Safety-as-a-Service using technology and behavioral science.

Food ReadySan Francisco, CA, USCompliance Softwareest. 2021Food ReadySan Francisco, CA, US · est. 2021

FoodReady: Streamlining compliance documentation and daily monitoring for food companies since 2021.

Seed · $5.5M30

Timothy Lu's Similar Executives & Operators

Achmad ZakyCo-Founder · Bukalapak

Lau Eng BoonBoard Member · Bukalapak

Willix HalimCEO · Bukalapak

Nugroho HerucahyonoCo-Founder · Bukalapak

Jay Geoffrey WacherBoard Member · Bukalapak

Soemantri BrodjonegoroBoard Member · Bukalapak

Bo ZhangCo-Founder · DiDi

WILL WEI CHENGBoard Member · DiDi

People Similar to Timothy Lu

Brian MillerBoard Member · Sentien Biotechnologies

Juan EnriquezFounder & CEO · Biotechonomy

John SantiniBoard Member · On Demand Therapeutics

Stéphane AttalCEO · Sentient Science